Protagonist Therapeutics PTGX 深 沪
已收盘 08-01 16:00:00 美东时间
53.83
-0.030
-0.06%
华盛通- 最 高55.49
- 今 开54.01
- 成交量 60.08万股
- 最 低 53.60
- 昨 收 53.86
- 总市值 33.36亿
- 52周最高 60.60
- 市盈率 静 12.73
- 换手率 0.97%
- 52周最低 33.31
- 委 比 58.63%
- 总股本 6198.20万
- 历史最高 60.60
- 量 比 1.03
- 振 幅 3.51%
- 历史最低 4.47
- 每 手 1
- 风险率 5.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics received a patent (JP 7714571B) in Japan for a modified stilbenoid to treat epilepsy and seizures. The patent, granted on July 18, 2025, provides exclusivity until March 2041. Colin Stott highlighted the importance of this patent, following its previous grant in the UK, and plans to expand its coverage in other territories. Japan's pharmaceutical market is the world's third largest, valued at over $85 billion in 2025 and e...
07-30 12:30
口服多肽向FDA递交上市申请 药明康德共同强生等参与
据药明康德（603259.SH）官微7月22日消息，药明康德共同强生（Johnson & Johnson）与Protagonist Therapeut...
07-22 09:22
Protagonist Therapeutics And Johnson & Johnson Submit NDA For Icotrokinra, A First-in-Class Oral IL-23 Receptor Blocker, Following Phase 3 Results In Plaque Psoriasis
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four Phase 3 studies,
07-21 20:06
新浪财经ESG：PTGX MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-28 07:00
Protagonist Therapeutics to Reveal Oral Obesity Drug Development Candidate and Study Results in Upcoming Call
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and
06-26 19:09
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Citigroup Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $72
Citigroup analyst Geoff Meacham initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $72.
06-17 19:44
9 Analysts Assess Protagonist Therapeutics: What You Need To Know
In the latest quarter, 9 analysts provided ratings for Protagonist Therapeutics...
06-03 20:01
Reported Sunday, Protagonist And Takeda Present 32-Week VERIFY Data: Rusfertide Significantly Reduces Phlebotomy, Improves Symptoms In Polycythemia Vera
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care,
06-02 15:42
强生亮出底牌
（转自：药剂Talks） 强生频繁亮出新王牌，按下了自免王座争夺战的加速键。 4月30日，强生的FcRn阻断剂Nipocalimab（尼卡利单抗）获FDA批准...
05-22 19:06
